REGENXBIO Inc. (RGNX): Operating Cash Flow
-$123.96M
Year ended 2025-12-31
-$246.67M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$123.96M | n/m | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | -$173.12M | n/m | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | -$218.41M | n/m | 2025-03-13, From 2023-01-01 |
| 2022-12-31 | -$207.49M | n/m | 2025-03-13, From 2022-01-01 |
| 2021-12-31 | $218.88M | n/m | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | -$54.06M | n/m | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | -$107.70M | n/m | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $104.65M | n/m | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | -$57.99M | n/m | 2020-02-26, From 2017-01-01 |
| 2016-12-31 | -$48.56M | n/m | 2019-02-27, From 2016-01-01 |
| 2015-12-31 | -$22.52M | n/m | 2018-03-06, From 2015-01-01 |
| 2014-12-31 | -$2.40M | n/m | 2017-03-07, From 2014-01-01 |
| 2013-12-31 | -$3.01M | n/a | 2016-03-03, From 2013-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | 2025-12-31 | -$123.96M | n/m |
| Ginkgo Bioworks Holdings, Inc. (DNA) | 2025-12-31 | -$171.06M | n/m |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | -$73.21M | n/m |
| Beam Therapeutics Inc. (BEAM) | 2025-12-31 | -$345.10M | n/m |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | -$22.80M | n/m |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $7.71M | n/m |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | -$50.94M | n/m |
| Agenus Inc (AGEN) | 2025-12-31 | -$77.19M | n/m |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | -$304.94M | n/m |
Compare RGNX, DNA, ADAPY, BEAM side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗